Teleflex Incorporated (TFX) Cash Flow Statement
A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.
Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally.
Total Cash From Operating Activities Chart for Teleflex Incorporated
Teleflex Incorporated (TFX) operating cash flow for FY2025 was USD 340.7M, a -46.4% change from FY2024. Teleflex Incorporated's operating cash flow grew from USD 21.7M in 1989 to USD 340.7M in 2025 (1469.9% over 36 years). Operating cash flow compound annual growth rate: 5-year CAGR of -4.8%, 10-year CAGR of 1.3%, 20-year CAGR of 0.1%.
Total Cash From Operating Activities (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $5.77B
- Implied Share Price
- $136.29
- Enterprise Value
- $7.86B
- Revenue (TTM)
- $2.25B
- EBITDA
- $403.90M
- Profit Margin
- -45.76%
- Trailing P/E
- —
- Forward P/E
- 11.01
- Price/Book (MRQ)
- 1.82
- Price/Sales (TTM)
- 2.56
- EV/EBITDA
- 30.73
- EV/Revenue
- 3.49
- Dividend Yield
- 1.00%
- Book Value
- $68.55
- Free Cash Flow (FY2025)
- $245.44M
- Free Cash Flow Yield
- 4.25%
Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.